Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Caribou Biosciences, Inc. reported revenue of $11M, up 11.7% year over year. Operating margin was -1329.4% and net margin -1327.4%, on a free-cash-flow margin of -1006.8% with capital expenditure at 12.2% of revenue. Every figure is computed directly from CRBU's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $11M | -1329.4% | -1327.4% |
| FY2024 | $10M | -1667.2% | -1491.9% |
| FY2023 | $34M | -336.6% | -296.1% |
| FY2022 | $14M | -768.2% | -717.8% |
| FY2021 | $10M | -697.8% | -697.3% |
How does CRBU compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.